Kroskey added that the folded radius forms as the metal is forced upward, in contact with the nose of the clamping tool, ...

Discover the core features of Claude Design, from setting up custom branding to exporting code-based designs to Figma and ...

CSL chief financial officer Ken Lim says the global healthcare giant is trying to simplify its organisation after conceding that a slowdown in its ability to make quick decisions had hurt its ...

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst ...

View post: Mazda Files for RX-8 Trademark Again—And a Comeback Could Be Next The 2027 M4 Coupe M Legacy Edition celebrates 40 years since the M3 Coupe debuted. Only 40 units will be produced, ...

BRADLEY, Ill. -- Australian biopharmaceutical company CSL announced Monday a major expansion at its Kankakee manufacturing facility, a move that will bring end-to-end plasma processing into the U.S.

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The Melbourne-based company will ...

Eli Lilly has been scouting for drugs to follow the trail blazed by its blockbuster cardiometabolic medicines. Its latest pipeline-building deal has the pharmaceutical company paying $100 million for ...

Feb ⁠18 (Reuters) - ⁠Australia's CSL said on Wednesday it had entered into an exclusive ⁠licensing ⁠agreement with ⁠Eli Lilly and Co, granting it certain ⁠rights to develop ⁠and commercialise ...

But this week, following profit downgrades and yet more upheaval at the top, CSL is sickly. The abrupt “retirement” of chief executive Paul McKenzie, announced just 24 hours before a disastrous 81 per ...

Let's start with CSL's leadership change, because it sets the tone. Paul McKenzie has stepped down as chief executive, and the board has appointed long-time CSL executive and current director Gordon ...

CSL announced the exit of Paul McKenzie as chief executive. Senior executive Gordon Naylor appointed interim CEO. Shares of Australian biotech firm CSL plunged to an 8-year low Wednesday after it ...